These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23314259)

  • 1. Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia.
    Mapelli P; Mangili G; Picchio M; Gentile C; Rabaiotti E; Giorgione V; Spinapolice EG; Gianolli L; Messa C; Candiani M
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):505-13. PubMed ID: 23314259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of chest CT scan in gestational trophoblastic neoplasia with lung metastasis].
    Cheng Y; Ma FH; Wang XR; Le XN; Zhang GF; Lu X
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):384-389. PubMed ID: 29961280
    [No Abstract]   [Full Text] [Related]  

  • 3. [18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients.
    Sironi S; Picchio M; Mangili G; Garavaglia E; Zangheri B; Messa C; Voci C; Taccagni GL; del Maschio A; Fazio F
    Gynecol Oncol; 2003 Oct; 91(1):226-30. PubMed ID: 14529686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia.
    Dhillon T; Palmieri C; Sebire NJ; Lindsay I; Newlands ES; Schmid P; Savage PM; Frank J; Seckl MJ
    J Reprod Med; 2006 Nov; 51(11):879-87. PubMed ID: 17165434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of 18F-fluorodeoxyglucose positron emission tomography in gestational trophoblastic tumours: a pilot study.
    Chang TC; Yen TC; Li YT; Wu YC; Chang YC; Ng KK; Jung SM; Wu TI; Lai CH
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):156-63. PubMed ID: 16220307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
    Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastasis detection with 18 FDG-positron emission tomography/computed tomography in gestational trophoblastic neoplasia: a report of 2 cases.
    Cortés-Charry R; Figueira LM; Nieves L; Colmenter L
    J Reprod Med; 2006 Nov; 51(11):897-901. PubMed ID: 17165437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
    Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
    Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas.
    Eugene T; Corradini N; Carlier T; Dupas B; Leux C; Bodet-Milin C
    Nucl Med Commun; 2012 Oct; 33(10):1089-95. PubMed ID: 22929116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary epithelioid trophoblastic tumor with a synchronous breast carcinoma detected only with FDG-PET/CT Scan.
    Kara T; Ozcan Kara P; Baba F; Celik C; Kara Gedik G
    Rev Esp Med Nucl; 2011; 30(6):368-71. PubMed ID: 21440960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
    Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
    Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma.
    Schüle SC; Eigentler TK; Garbe C; la Fougère C; Nikolaou K; Pfannenberg C
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):482-8. PubMed ID: 26384681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.